Prosonix Extends Series B Financing, Plans Generic Fluticasone Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
Prosonix receives an extra $9 million for its Series B round as it changes business strategy from contract research to the development of generic respiratory products, based on a novel particle-engineering technology for inhaled powders.
You may also be interested in...
Mylan, Prosonix Use In Vitro Data To File Generic Fluticasone Inhaler In EU
Marketing submissions for generic inhaled respiratory products based on in vitro data alone may be less expensive and a quicker route to market than other EU regulatory processes for inhaled generics.
Deal Watch: Nanotech Formulations Of Doxorubicin Highlight Recent Deal-Making
France’s BioAlliance adds to its oncology portfolio through an all-equity merger with Topotarget; NanoSmart and NanoValent team up on an ovarian cancer program; Mylan licenses two respiratory therapies from Prosonix; and Actavis adds to its specialty generics portfolio with products from Akorn.
Financings Of The Fortnight: In The Aftermath Of Facebook IPO, Kythera Steps Up, TVAX And Cancer Genetics Back Off
Plus news on recent financing activity by TVM Capital, Royalty Pharma, Prosonix and Sangart.